MA39841A - Association d'un inhibiteur de l'egfr et d'un inhibiteur de mek dans le traitement de cancers présentant une mutation de nras - Google Patents

Association d'un inhibiteur de l'egfr et d'un inhibiteur de mek dans le traitement de cancers présentant une mutation de nras

Info

Publication number
MA39841A
MA39841A MA039841A MA39841A MA39841A MA 39841 A MA39841 A MA 39841A MA 039841 A MA039841 A MA 039841A MA 39841 A MA39841 A MA 39841A MA 39841 A MA39841 A MA 39841A
Authority
MA
Morocco
Prior art keywords
inhibitor
treatment
combination
mutated cancer
nras mutated
Prior art date
Application number
MA039841A
Other languages
English (en)
Inventor
Darren Anthony Edward Cross
Catherine Anne Eberlein
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd filed Critical Astrazeneca Ab
Publication of MA39841A publication Critical patent/MA39841A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés destinés à identifier une résistance à un traitement anticancéreux, en identifiant une mutation e63k de nras, une mutation g12v de nras ou une augmentation du nombre de copies du gène
MA039841A 2014-04-04 2015-04-02 Association d'un inhibiteur de l'egfr et d'un inhibiteur de mek dans le traitement de cancers présentant une mutation de nras MA39841A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461975088P 2014-04-04 2014-04-04
US201462013573P 2014-06-18 2014-06-18

Publications (1)

Publication Number Publication Date
MA39841A true MA39841A (fr) 2017-02-08

Family

ID=52824498

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039841A MA39841A (fr) 2014-04-04 2015-04-02 Association d'un inhibiteur de l'egfr et d'un inhibiteur de mek dans le traitement de cancers présentant une mutation de nras

Country Status (15)

Country Link
US (2) US20200237758A1 (fr)
EP (1) EP3125885B1 (fr)
JP (1) JP6549147B2 (fr)
KR (1) KR102406334B1 (fr)
CN (1) CN106456774A (fr)
AU (1) AU2015242407B2 (fr)
CA (1) CA2943402C (fr)
DK (1) DK3125885T3 (fr)
ES (1) ES2890556T3 (fr)
HU (1) HUE055747T2 (fr)
MA (1) MA39841A (fr)
MX (1) MX369111B (fr)
PL (1) PL3125885T3 (fr)
RU (1) RU2683276C2 (fr)
WO (1) WO2015150826A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
WO2018218633A1 (fr) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Polythérapies pour le traitement de cancers
WO2019195959A1 (fr) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Polythérapie pour cancers à mutation de braf
AU2019253706A1 (en) * 2018-04-09 2020-11-26 G1 Therapeutics, Inc. Treatment of cancers having driving oncogenic mutations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492568A1 (fr) * 2002-04-08 2005-01-05 SmithKline Beecham Corporation Methode de traitement du cancer consistant a administrer un inhibiteur de la famille erb et un inhibiteur de raf et/ou de ras
JP2012508240A (ja) * 2008-11-11 2012-04-05 イーライ リリー アンド カンパニー Ｐ７０ｓ６キナーゼ阻害剤およびｅｇｆｒ阻害剤の併用療法
SI2736895T1 (sl) * 2011-07-27 2016-03-31 Astrazeneca Ab Derivati 2-(2,4,5-substituiranega-anilino) pirimidina, kot modulatorji EGFR uporabni za zdravljenje raka
BR112014012539B1 (pt) * 2011-11-23 2022-12-20 Medimmune, Llc Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo
WO2013170066A1 (fr) * 2012-05-09 2013-11-14 H. Lee Moffitt Cancer Center & Research Institute, Inc. Peptides pour le traitement du cancer
US9783513B2 (en) * 2012-08-16 2017-10-10 Ohio State Innovation Foundation STAT3 inhibitors and their anticancer use
US20140066465A1 (en) * 2012-09-04 2014-03-06 The Cleveland Clinic Foundation CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS

Also Published As

Publication number Publication date
HUE055747T2 (hu) 2021-12-28
EP3125885A1 (fr) 2017-02-08
CA2943402C (fr) 2022-12-13
CN106456774A (zh) 2017-02-22
PL3125885T3 (pl) 2021-12-06
CA2943402A1 (fr) 2015-10-08
WO2015150826A1 (fr) 2015-10-08
KR20160135362A (ko) 2016-11-25
RU2016140626A3 (fr) 2018-10-23
JP2017511341A (ja) 2017-04-20
MX369111B (es) 2019-10-29
DK3125885T3 (da) 2021-09-27
EP3125885B1 (fr) 2021-06-30
RU2016140626A (ru) 2018-05-07
KR102406334B1 (ko) 2022-06-07
US20210177844A1 (en) 2021-06-17
RU2683276C2 (ru) 2019-03-27
ES2890556T3 (es) 2022-01-20
MX2016013048A (es) 2017-04-27
US20200237758A1 (en) 2020-07-30
AU2015242407B2 (en) 2017-11-09
AU2015242407A1 (en) 2016-10-13
JP6549147B2 (ja) 2019-07-24

Similar Documents

Publication Publication Date Title
HK1253093A1 (zh) 診斷和治療癌症的方法
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2018010362A (es) Metodos y sistemas para evaluar carga mutacional de tumores.
SG10201806656UA (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
IL252610A0 (en) Methods and preparations for the treatment of cancer
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
IL252766A0 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
MX2017012824A (es) Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
ZA201902320B (en) 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP3156483A4 (fr) Kit ou dispositif de détection du cancer de la prostate, et procédé de détection associé
EP3143163A4 (fr) Mutations géniques et altérations du nombre de copies de egfr, kras et met
HK1247577A1 (zh) Egfr突變陽性的非小細胞肺癌的聯合療法
HK1251168A1 (zh) 用於治療和/或預防腫瘤的沙粒病毒和產生具有(改善的)腫瘤消退特性的沙粒病毒的方法
EP3126525A4 (fr) Procédé et kits d'identification d'inhibiteurs de cdk9 pour le traitement du cancer
SG11201609921VA (en) Method and apparatus of usb 3.1 retimer presence detect and index
PH12017500881B1 (en) Aurora a kinase inhibitor
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
SG11201607298QA (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MA39841A (fr) Association d'un inhibiteur de l'egfr et d'un inhibiteur de mek dans le traitement de cancers présentant une mutation de nras
GB201419167D0 (en) Molecular and bioinformatics methods for direct sequencing
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
PH12016501838A1 (en) Compounds and their methods of use
EP3531830A4 (fr) Méthodes et compositions d'identification et de traitement de patients atteints d'un cancer du poumon à petites cellules